Plain-English translation of NCT03866382 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a treatment combination for people with rare types of bladder, kidney, and genitourinary cancers that have spread to other parts of the body. The combination includes cabozantinib, , and —two drugs that help your immune system fight cancer, plus one drug that targets cancer cells directly. Researchers want to see if this three-drug approach can shrink these tumors and help people live longer.
These rare genitourinary cancers are difficult to treat and have limited treatment options. This medication combination has shown promise in other cancers, and researchers want to learn whether it can work for these harder-to-treat, uncommon types.
You likely qualify if…
You likely don't qualify if…
You would take cabozantinib by mouth once daily and receive two intravenous infusions ( and ) on the first day of each treatment cycle. The first four cycles last 21 days each, and subsequent cycles last 28 days. This continues for up to 2 years unless your disease gets worse or side effects become too severe. You'll have regular blood tests, imaging scans (CT or MRI), and possibly bone scans to monitor how you're responding to the treatment.
AI-generated summary from trial data · Jun 15, 2026 · Not medical advice
United States